Redox active plasma iron in C282Y/C282Y hemochromatosis

Blood - Tập 105 - Trang 4527-4531 - 2005
Caroline Le Lan, Olivier Loréal, Tally Cohen, Martine Ropert, Hava Glickstein, Fabrice Lainé, Michel Pouchard, Yves Deugnier, André Le Treut, William Breuer, Z. Ioav Cabantchik, Pierre Brissot

Tóm tắt

Abstract

Labile plasma iron (LPI) represents the redox active component of non–transferrin-bound iron (NTBI). Its presence in thalassemic patients has been recently reported. The aim of the present study was to quantify LPI in HFE genetic hemochromatosis (GH) and to characterize the mechanisms accounting for its appearance. We studied 159 subjects subdivided into the following groups: (1) 23 with iron overloaded GH; (2) 14 with iron-depleted GH; (3) 26 with dysmetabolic hepatosiderosis; (4) 33 with alcoholic cirrhosis; (5) 63 healthy controls. Both NTBI and LPI were substantially higher in patients with iron-overloaded GH than in those with iron-depleted GH or in healthy controls. LPI was significantly correlated with serum transaminase increase in this group. LPI was elevated in the alcoholic cirrhosis subgroup of severely affected patients. LPI was found essentially when transferrin saturation exceeded 75%, regardless of the etiologic condition. Transferrin saturation above 75% was related to iron overload in GH and to liver failure in alcoholic cirrhosis. LPI is present in C282Y/C282Y hemochromatosis and may be a marker of toxicity due to its potential for catalyzing the generation of reactive oxygen radicals in vivo.


Tài liệu tham khảo

Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40: 255-263. Brissot P, Loréal O. Role of non-transferrin-bound iron in the pathogenesis of iron overload and toxicity. Adv Exp Med Biol. 2002;509: 45-53. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990;186: 1-85. Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Rad Biol Med. 1990;9: 315-325. Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in β-thalassemia patients. Eur J Clin Inv. 2002;32: 55-60. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopatic haemochromatosis. Clin Sci. 1985;68: 463-467. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97: 792-798. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic haemochromatosis: characterization by high performance liquid chromatography and nuclear resonance spectroscopy. Biol Chem. 1989;264: 4417-4422. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest. 2002;32(suppl 1): 50-54. Gosriwatana I, Loréal O, Shuli L, Brissot P, Porter J, Hider RC. Quantification of non-transferrin bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999;273: 212-220. Loréal O, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC. Determination of non-transferrin bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol. 2002;32: 727-733. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin bound iron. Anal Biochem. 1990;186: 320-323. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound-iron. Anal Biochem. 2001;299: 194-202. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102: 2670-2677. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded betathalassaemia/HbE patients treated with an oral chelator. Blood. 2004;104: 1504-1510. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2002;32(suppl 1): 42-49. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117: 1155-1163. Moirand R, Mortaji A, Loréal O, Paillard F, Brissot P, Deugnier Y. Liver iron overload with normal transferrin saturation: a new syndrome. Lancet. 1997;349: 95-97. De Feo TM, Fargion S, Duca L, et al. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res. 2001;25: 1494-1499. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. British J Surg. 1973;60: 646-649. Jouanolle AM, Fergelot P, Gandon G, Yaouang J, Le Gall JY, David V. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet. 1997;100: 544-547. Barry M, Sherlock S. Measurement of liver-iron concentration in needle-biopsy specimen. Lancet. 1971;2: 100-103. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology. 1994;193: 533-538. Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363: 357-362. Brissot P, Deugnier Y, Le Treut A, Regnouard F, Simon M, Bourel M. Ascorbic acid status in idiopathic haemochromatosis. Digestion. 1978;17: 479-487. Young IS, Trouton TG, Torney JJ, McMaster D, Callender ME, Trimble ER. Antioxidant status and lipid peroxidation in hereditary haemochromatosis. Free Radic Biol Med. 1994;16: 393-397. Brissot P, Guyader D, Loréal O, et al. Clinical aspects of hemochromatosis. Transfus Sci. 2000;23: 193-200. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101: 91-96.
Thông tin
Thông tin xuất bản

Blood

Tập 105

4527-4531

Thông tin tác giả